Aspen Biosciences
banner
aspenbio.bsky.social
Aspen Biosciences
@aspenbio.bsky.social
Pinned
Does your drug discovery strategy feel like... AI-fueled robot monkeys hammering away and hoping for a miracle? 🐒🤖

youtu.be/R0n__5HOOe8?...

#Biotech #DrugDiscovery #Pharma #DigitalTransformation #AI #Automation #Science
Digital Transformation with Robot Monkeys
YouTube video by Aspen Biosciences
youtu.be
Is your AI strategy stuck in "Pilot Purgatory"? 🧬💻

Our new whitepaper "From Hype To Implementation" deconstructs the biopharma AI success story from hype to clinical implementation.

bit.ly/3YzVNa2

#DrugDiscovery #GenAI #Biotech #AI
- YouTube
Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
bit.ly
January 9, 2026 at 4:00 PM
The 2025 AI State of Play is here. 🧬 AI-native drugs are hitting 80-90% Phase I success rates, fundamentally challenging Eroom's Law. This short video explainer fills in the details.

youtu.be/4BDoeGxy_ns

#AI #DrugDiscovery
AI State of Play 2025
The AI State of Play 2025 highlights a watershed year where AI-discovered molecules achieved Phase I clinical success rates of 80-90%, significantly outperforming the historical average of 40-65%. The report identifies five structural pillars: Big Pharma "AI Factories": Companies like Eli Lilly and Pfizer are building massive internal computational infrastructures and reducing discovery timelines for small molecules to just 30 days. TechBio Maturity: Companies like Insilico Medicine achieved a "Penicillin Moment" with positive Phase 2a results for the first entirely AI-native drug. Democratized Modeling: Open-source tools like Boltz-2 and OpenFold3 have commoditized high-accuracy molecular modeling. The "Agentic" Shift: A move toward autonomous systems that can independently formulate hypotheses and execute experiments. Regulatory Adaptation: Increased focus on biologics (13-year protection) over small molecules (9-year protection) due to the Inflation Reduction Act (IRA). Download the AI State of Play 2025 to learn more: https://drive.google.com/file/d/1a6etlnbgWyC2PbZIZGGXWLCJ-saA4BSO/view?usp=drive_link
youtu.be
January 8, 2026 at 4:00 PM
The biotech industry entered a phase of "disciplined resilience" in 2025. While venture funding is rebounding—surging 70% in Q3 alone—the capital is being tethered to clinical validation like never before.

This explainer gives you all of the highlights.
bit.ly/3NfNn59
State of Play 2025
What does the "State of Play" look like for the biotech and pharma industry in 2025? In this explainer, we take a look at some of the changes over the last year—from a resurgence in funding for high-value assets to the incredible speed of AI-driven drug discovery (did you know Pfizer is hitting 30-day discovery cycles?). For more details, read our free State of Play 2025 whitepaper. https://drive.google.com/file/d/1E1y6RRas74I2a4A1lFhZwZE2F9sDQucH/view?usp=drive_link
bit.ly
January 8, 2026 at 12:08 AM
AI-native drugs are hitting 80-90% Phase I success rates. From Pfizer's 30-day discovery cycle to the rise of Agentic AI, see how #AI is transforming #DrugDiscovery.

drive.google.com/file/d/1a6et...

#TechBio #BioPharma #JPM26 #JPM
January 5, 2026 at 2:00 PM
The 2025 Biotech "State of Play" is here. 🔬
We’re seeing massive shifts:
AI-Driven Improvements in productivity, timelines, and success rates.
M&A deal values up 31%.
$350B in rev. at risk by 2029.
Ready for recalibration?
drive.google.com/file/d/1E1y6...

#Biotech #Innovation #AI #JPM26
December 31, 2025 at 6:50 PM
Reposted by Aspen Biosciences
A retreat from investments in drugs and vaccines will leave the U.S. less prepared for the next viral scourge, experts warn. https://scim.ag/47F3Yap
The Trump administration is dismantling efforts to fight the next pandemic
A retreat from investments in drugs and vaccines leaves U.S. less prepared for the next viral scourge, experts warn
scim.ag
November 13, 2025 at 11:19 PM
Reposted by Aspen Biosciences
We're excited to present LeaVS, a method to scale up learning for protein function models. It is based on the co-design of wet lab experiments and in silico training.
October 21, 2025 at 2:38 PM
Reposted by Aspen Biosciences
Tests of large language models reveal that they can behave in deceptive and potentially harmful ways. Nature reports on what these results mean for the future of AI. 🧪
AI models that lie, cheat and plot murder: how dangerous are LLMs really?
Tests of large language models reveal that they can behave in deceptive and potentially harmful ways. What does this mean for the future?
go.nature.com
October 22, 2025 at 1:44 AM
Does your drug discovery strategy feel like... AI-fueled robot monkeys hammering away and hoping for a miracle? 🐒🤖

youtu.be/R0n__5HOOe8?...

#Biotech #DrugDiscovery #Pharma #DigitalTransformation #AI #Automation #Science
Digital Transformation with Robot Monkeys
YouTube video by Aspen Biosciences
youtu.be
October 20, 2025 at 4:57 PM
Reposted by Aspen Biosciences
for 10 years I have been giving an introduction into protein structure at the Zuyd applied university (two short lectures, two short practicals).

We have been using Proteopedia, because it is Open, it is free, it is interactive, and is powered by Jmol […]

[Original post on social.edu.nl]
October 20, 2025 at 4:01 PM
The pandemic taught us we can do six impossible things before breakfast —like getting new medicines to patients faster by collaborating across time zones 24/7.

Now, that "impossible" pace is the daily routine.

#DrugDiscovery #Biotech #Science #Rnd #Pharma #Innovation
6 Impossible Things
YouTube video by Aspen Biosciences
youtu.be
October 20, 2025 at 4:36 PM
#DigitalTransformation is the process of applying technologies like #AI, #automation and advanced analytics to fundamentally change #DrugDiscovery, in ways that measurably reduce costs and timelines, improve capital efficiency and create a more lean and agile research organization.
The Digital Transformation Roadmap - Aspen Biosciences
The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practica...
aspenbiosciences.com
September 20, 2025 at 6:21 AM
In our series "Across The Great Divide" we're taking a look at the "Great Divide" between drug discovery and drug development projects and how drug discovery project planning can improve the capital efficiency of your programs and the…

https://aspenbiosciences.com/across-the-great-divide-part-2/
May 23, 2025 at 5:19 PM
Reposted by Aspen Biosciences
Chemists Stuart Schreiber of Harvard University and Arena BioWorks and Peter Schultz of @scripps.edu will split the 2025 Welch Award in Chemistry for their work in the field of chemical biology. cen.acs.org/people/award... #chemsky🧪
2025 Welch Award honors chemical biologists
Recipients Schreiber and Schultz will each receive $500K prize for work on chemical probes, unnatural amino acids, and new therapeutics
cen.acs.org
May 22, 2025 at 7:51 PM
Reposted by Aspen Biosciences
Health secretary RFK Jr. names familiar culprits for the "sickest generation," even where evidence is lacking

www.statnews.com/2025/05/22/r...
4 takeaways from the MAHA commission’s report on children’s health
The MAHA commission's assessment of children's health mirrored RFK Jr.'s familiar targets. The question now is what remedies they will recommend.
www.statnews.com
May 22, 2025 at 8:32 PM
Reposted by Aspen Biosciences
The full panel discussion from our “Era of TechBio” event at #JPM25 is online! Hear from leading voices at the intersection of investment, technology & healthcare discussing the latest wins & remaining obstacles & how breakthroughs like LLMs & AI agents are allowing us to scale. youtu.be/GM9l8Pi8CYs
Recursion's "Era of TechBio" Panel at JPM Featuring Dean Li, Kimberly Powell, Alex Gorsky & Tony Kim
YouTube video by Recursion
youtu.be
February 12, 2025 at 6:52 PM